{"ticker": {"uuid": "366586d2-092c-45d6-ad58-48b363f0a023", "symbol": "EXEL", "name": "Exelixis Inc", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Exelixis falls as final analysis of zanzalintinib phase 3 data disappoints", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOd3NUMmVlc2dfT1ZTMGZoaGlpUVhqQzg5VVJ5bWZUZXBvbVdNVHZOZzMzcENCWFpxUFZmR3NWa3ZLa3daSTZBR3RseUFhTjJHbmNNRFRWU1pyNzl3VXJGRUsxbG1GMGFlQ3Y5YjZrcVJrSXdJV1NHVjFkZkRmY1VGM0h1NmJVR3A5aWNNVzNWQVRNaGxvNlc1TjdiSkhyMmdxTXZ6N1JrVE1kZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-22T15:14:23+00:00", "published_display": "22 Jun 2026 15:14", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis Stock - weekly review and biotech sector context", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNV09NdjFDWDhnbGl5ZDg2eHdKWU5aemstR1pCeVNVMTJJSWFfOW5Ud2VYYlc0Vk9JSEdoRUVXOEk5YkZIRjNaaXc1bi1Td0Z3ajNFWEFhOGtkLTBfVXFrRldvWjA5ODVxQnNuem9zM0VESlYySVhJd194YkNHMlR0NFNkQTVqd3lVMFp6NFBwcmVacE1KRm1LbXZLcDE2WXNfdFlFckNLOEY1UWd0bXpaTWpEZUY?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-19T20:46:53+00:00", "published_display": "19 Jun 2026 20:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis Inc (EXEL) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Exelixis Inc (EXEL), highlighting its current earnings forecast score, analyst ratings, and price targets. It details expected EPS and revenue for upcoming quarters and compares EXEL's analyst ratings to its peers in the Biotechnolog", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-exel/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T09:10:21", "published_display": "18 Jun 2026 09:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis Inc (EXEL) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Exelixis Inc (EXEL) demonstrates robust financial health with a score of 8.96, ranking 21st in the Biotechnology & Medical Research industry. The company reported a significant year-over-year revenue increase of 9.97% to $610.81M and a net profit increase of 31.86%. This strong p", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-exel/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T06:10:22", "published_display": "18 Jun 2026 06:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To Exelixis (EXEL) CABOMETYX Neuroendocrine Tumor Phase 3 Win at ASCO", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-17T14:57:27+00:00", "published_display": "17 Jun 2026 14:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis Inc (EXEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Exelixis Inc (EXEL), categorizing its income by business segments and geographical regions. As of April 6, 2025, CABOMETYX is the primary revenue driver, contributing 91.09% of the total, with the U.S. market dominating regio", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-exel/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T08:41:23", "published_display": "17 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis Inc (EXEL) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides an overview of Exelixis Inc's (EXEL) shareholder structure, listing major institutional holders and their proportion of shares. It details shareholder types, institutional shareholding trends over recent quarters, and individual shareholder activity with cha", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-exel/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T08:41:23", "published_display": "17 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis Inc Stock (US30161Q1040): Quarterly earnings in focus after recent results", "summary": "Exelixis Inc reported its first-quarter 2024 financial results, showing revenue growth driven primarily by its flagship cancer drug, Cabometyx. The company also provided an updated 2024 financial outlook, projecting continued revenue growth despite increased R&D spending to furth", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exelixis-inc-stock-us30161q1040-quarterly-earnings-in-focus-after/69545115", "source_name": "AD HOC NEWS", "published_at": "2026-06-15T14:09:24", "published_display": "15 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why (EXEL) Price Action Is Critical for Tactical Trading", "summary": "This article from Stock Traders Daily discusses the critical price action of Exelixis Inc. (NASDAQ: EXEL) for tactical trading, based on AI-driven analysis. It highlights strong sentiment across all time horizons, indicating an overweight bias, and identifies potential upside. Th", "url": "https://news.stocktradersdaily.com/news_release/20/Why_EXEL_Price_Action_Is_Critical_for_Tactical_Trading_061526040402_1781510642.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-15T04:04:00", "published_display": "15 Jun 2026 04:04", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis CABINET Win Extends CABOMETYX Reach And Raises Valuation Questions", "summary": "Exelixis reported positive phase 3 CABINET trial results for CABOMETYX in advanced neuroendocrine tumors, demonstrating significant improvement in progression-free survival. This extends the potential reach of CABOMETYX, but given the stock's strong performance, investors are eva", "url": "https://sg.finance.yahoo.com/news/exelixis-cabinet-win-extends-cabometyx-200859000.html", "source_name": "Market source", "published_at": "2026-06-13T20:08:00", "published_display": "13 Jun 2026 20:08", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs Group Inc. Purchases 1,113,916 Shares of Exelixis, Inc. $EXEL", "summary": "Goldman Sachs Group Inc. significantly increased its stake in Exelixis, Inc. (NASDAQ:EXEL) during the fourth quarter, purchasing over 1.1 million additional shares, raising its total holding to 2.1 million shares valued at approximately $92.7 million. Following this news, Exelixi", "url": "https://www.marketbeat.com/instant-alerts/filing-goldman-sachs-group-inc-purchases-1113916-shares-of-exelixis-inc-exel-2026-06-10/", "source_name": "MarketBeat", "published_at": "2026-06-11T03:39:16", "published_display": "11 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cibc World Market Inc. Purchases 31,985 Shares of Exelixis, Inc. $EXEL", "summary": "Cibc World Market Inc. significantly increased its stake in Exelixis, Inc. by 462.3% in the fourth quarter, adding 31,985 shares to hold a total of 38,904 shares valued at $1.705 million. This move is part of a broader trend, with other institutional investors also boosting their", "url": "https://www.marketbeat.com/instant-alerts/filing-cibc-world-market-inc-purchases-31985-shares-of-exelixis-inc-exel-2026-06-10/", "source_name": "MarketBeat", "published_at": "2026-06-10T16:39:28", "published_display": "10 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BI Asset Management Fondsmaeglerselskab A S Has $1.91 Million Position in Exelixis, Inc. $EXEL", "summary": "BI Asset Management Fondsmaeglerselskab A S significantly reduced its stake in Exelixis, Inc. by 74.9% in the fourth quarter, now holding 43,658 shares valued at approximately $1.91 million. This comes as several insiders, including CFO Christopher J. Senner and Director Sue Gail", "url": "https://www.marketbeat.com/instant-alerts/filing-bi-asset-management-fondsmaeglerselskab-a-s-has-191-million-position-in-exelixis-inc-exel-2026-06-10/", "source_name": "MarketBeat", "published_at": "2026-06-10T15:39:43", "published_display": "10 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis (EXEL) Valuation Check After CABINET Trial Data Fuels Renewed Growth Optimism", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bank of New York Mellon Corp Cuts Position in Exelixis, Inc. $EXEL", "summary": "Bank of New York Mellon Corp reduced its stake in Exelixis, Inc. by 12.3% during the fourth quarter, selling 285,584 shares. Despite this, other institutional investors like Goldman Sachs Group Inc. and BNP Paribas Financial Markets increased their holdings significantly. Exelixi", "url": "https://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-cuts-position-in-exelixis-inc-exel-2026-06-09/", "source_name": "MarketBeat", "published_at": "2026-06-10T03:39:16", "published_display": "10 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis stock hits all-time high at 52.98 USD By Investing.com", "summary": "Exelixis Inc. (EXEL) stock reached an all-time high of $52.98, reflecting a 24.86% increase over the past year. The biotechnology company, currently valued at $13.34 billion, shows an attractive P/E ratio of 17.08 and a PEG ratio of 0.42, suggesting undervaluation and strong near", "url": "https://ng.investing.com/news/company-news/exelixis-stock-hits-alltime-high-at-5298-usd-93CH-2550204", "source_name": "Investing.com Nigeria", "published_at": "2026-06-09T14:41:04", "published_display": "09 Jun 2026 14:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis, Inc. $EXEL Position Increased by Northwestern Mutual Wealth Management Co.", "summary": "Northwestern Mutual Wealth Management Co. significantly increased its stake in Exelixis, Inc. by 2,920.5% in the fourth quarter, now owning 25,040 shares valued at $1.1 million. This increase comes as Exelixis reported strong quarterly results, beating EPS estimates with $0.87 an", "url": "https://www.marketbeat.com/instant-alerts/filing-exelixis-inc-exel-position-increased-by-northwestern-mutual-wealth-management-co-2026-06-08/", "source_name": "MarketBeat", "published_at": "2026-06-09T04:10:42", "published_display": "09 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis, Inc. (EXEL) Stock Analysis: A Promising Player in Biotechnology with Strong Revenue Growth", "summary": "Exelixis, Inc. (EXEL) is highlighted as a significant player in the biotechnology sector, specializing in cancer treatments with products like CABOMETYX and COMETRIQ. The company demonstrates strong financial performance with 10% year-over-year revenue growth and a High ROE of 40", "url": "https://www.directorstalkinterviews.com/exelixis-inc-exel-stock-analysis-a-promising-player-in-biotechnology-with-strong-revenue-growth/4121253186", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-08T10:14:00", "published_display": "08 Jun 2026 10:14", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CABINET Results Broaden CABOMETYX Neuroendocrine Reach And Investor Considerations", "summary": "Exelixis, Inc. reported new phase 3 CABINET trial data for CABOMETYX in advanced neuroendocrine tumors, showing significant improvements in progression-free survival regardless of tumor functional status. These results expand the clinical evidence for CABOMETYX and reinforce its ", "url": "https://www.sahmcapital.com/news/content/cabinet-results-broaden-cabometyx-neuroendocrine-reach-and-investor-considerations-2026-06-06", "source_name": "Sahm", "published_at": "2026-06-07T01:39:52", "published_display": "07 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis director Sue Eckhardt sells $491,973 in stock", "summary": "Exelixis director Sue Eckhardt sold 9,812 shares of the company's common stock for $491,973 on June 1, 2026, as part of a Rule 10b5-1 trading plan. The sale occurred while the stock was near its 52-week high, though InvestingPro analysis suggests it is still undervalued with exce", "url": "https://www.investing.com/news/insider-trading-news/exelixis-director-sue-eckhardt-sells-491973-in-stock-93CH-4725458", "source_name": "Investing.com", "published_at": "2026-06-04T13:40:32", "published_display": "04 Jun 2026 13:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis director Jack Wyszomierski sells $198,408 in shares", "summary": "Jack L. Wyszomierski, a director at Exelixis Inc. (NASDAQ:EXEL), recently sold 3,925 shares of the company's common stock for $198,408. This transaction was executed under a Rule 10b5-1 trading plan. The article also notes Exelixis' strong financial performance in Q1 2026 and its", "url": "https://www.investing.com/news/insider-trading-news/exelixis-director-jack-wyszomierski-sells-198408-in-shares-93CH-4725459", "source_name": "Investing.com", "published_at": "2026-06-04T12:40:30", "published_display": "04 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNbE5NTHBCdDV1S1Y0b2hJTU9SbmdNTi1yRV9SYzNUOVhYYzR1R1FtdGtnTjVOWk02akNVMV94VENqUmw2dWdRNzJqNXhyOGxaNVpxOHd4alhBaUhBYVU5NzJ4bGF5VVA3YzFNdlBMTHotcVZCd2ZHSG9EQ1hGb05RV1l5dVlnM080aVpTTlp0bFBIU3hoWHllMw?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EXEL Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article provides a detailed financial analysis of Exelixis Inc (EXEL), outlining its revenue breakdown, profitability margins, and a comparison with key competitors RGC and MDGL. It highlights that CABOMETYX is the primary revenue driver, contributing 90.3% of total sales, a", "url": "https://intellectia.ai/en/stock/EXEL/financials", "source_name": "Intellectia AI", "published_at": "2026-06-04T04:39:16", "published_display": "04 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] EXELIXIS, INC. SEC Filing", "summary": "This SEC filing refers to a Form 144 filed by Exelixis, Inc. (EXEL) on June 1, 2026, indicating a proposed sale of securities. The document outlines the information required for such a sale under Rule 144, including details about the securities to be sold (9812 shares of common s", "url": "https://www.stocktitan.net/sec-filings/EXEL/144-exelixis-inc-sec-filing-06e92a1a37bb.html", "source_name": "Stock Titan", "published_at": "2026-06-04T03:09:27", "published_display": "04 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell Alert: Jack Wyszomierski Sells 3,925 Shares of Exelixis Inc (EXEL)", "summary": "Jack Wyszomierski, a Director at Exelixis Inc (EXEL), sold 3,925 shares of the company on June 1, 2026, increasing his total sales over the past year to 103,499 shares. Exelixis, a biotechnology company focused on cancer treatments, has seen 1 insider buy and 21 insider sells in ", "url": "https://www.gurufocus.com/news/8900093/insider-sell-alert-jack-wyszomierski-sells-3925-shares-of-exelixis-inc-exel", "source_name": "GuruFocus", "published_at": "2026-06-04T00:11:42", "published_display": "04 Jun 2026 00:11", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Planned share sale by Exelixis (NASDAQ: EXEL) director Wyszomierski", "summary": "Exelixis director Jack L. Wyszomierski sold 3,925 shares of common stock at $50.55 per share on June 1, 2026. This transaction was part of a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following the sale, he directly holds 284,384 shares, with an additional 8,", "url": "https://www.stocktitan.net/sec-filings/EXEL/form-4-exelixis-inc-insider-trading-activity-6ef5b77ec34f.html", "source_name": "Stock Titan", "published_at": "2026-06-03T23:10:06", "published_display": "03 Jun 2026 23:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis (EXEL) director Eckhardt sells 9,812 shares under 10b5-1 plan", "summary": "Exelixis (EXEL) director Sue Gail Eckhardt sold 9,812 shares of common stock at a weighted average price of $50.14 per share on June 1, 2026, under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, her total holdings include 16,079 shares, which account for rest", "url": "https://www.stocktitan.net/sec-filings/EXEL/form-4-exelixis-inc-insider-trading-activity-f7ad9d426627.html", "source_name": "Stock Titan", "published_at": "2026-06-03T23:10:06", "published_display": "03 Jun 2026 23:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis Jumps 5.0% Amid Sector-Wide Rally", "summary": "Exelixis, Inc. saw its stock price surge by 5.0% to $50.99 on Wednesday, driven by a broader rally in the biotechnology sector. This rise, which included similar gains for several peer companies like Incyte and Moderna, was attributed to sector-wide momentum rather than any speci", "url": "https://news.alphastreet.com/exelixis-jumps-5-0-amid-sector-wide-rally/", "source_name": "AlphaStreet", "published_at": "2026-06-03T17:10:06", "published_display": "03 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Exelixis (EXEL) is a Top Value Stock for the Long-Term", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQemt0SXozdDh4S29GS2taZXJ1SEpqLXVSOElobU12RmtMR0RmckFVNEpNcWpKODZCblpvSmpqRmhfMzQtcl9HSlBYaXEyeGFwNmZ3UHk2VF9QRjBXeGc1Rmx1UFZFb3B1TjJSN0ZhTS04anVFcTNtN3dKT25fRjlvN1h6Mm1sQkxaT2FsOFVsV2dpRzZYVUFN?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis, Inc. $EXEL Shares Purchased by BNP Paribas Financial Markets", "summary": "BNP Paribas Financial Markets significantly increased its stake in Exelixis, Inc. (NASDAQ:EXEL) by 79.5% during the fourth quarter, bringing its total holdings to over 1.1 million shares valued at approximately $49 million. This increase follows Exelixis reporting better-than-exp", "url": "https://www.marketbeat.com/instant-alerts/filing-exelixis-inc-exel-shares-purchased-by-bnp-paribas-financial-markets-2026-06-03/", "source_name": "MarketBeat", "published_at": "2026-06-01T17:09:24", "published_display": "01 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis presents Cabometyx data for neuroendocrine tumors", "summary": "Exelixis (NASDAQ:EXEL) presented positive subgroup analysis data from its phase 3 CABINET trial for Cabometyx in neuroendocrine tumors at the American Society of Clinical Oncology Annual Meeting. The results showed a significant reduction in the risk of disease progression or dea", "url": "https://www.investing.com/news/company-news/exelixis-presents-cabometyx-data-for-neuroendocrine-tumors-93CH-4717767", "source_name": "Investing.com", "published_at": "2026-05-31T11:10:13", "published_display": "31 May 2026 11:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis presents Cabometyx data for neuroendocrine tumors By Investing.com", "summary": "Exelixis (NASDAQ:EXEL) has released positive subgroup analysis results from its Phase 3 CABINET trial for Cabometyx in advanced neuroendocrine tumors. The study showed significant reduction in disease progression or death risk in both functional and non-functional tumor patients.", "url": "https://au.investing.com/news/stock-market-news/exelixis-presents-cabometyx-data-for-neuroendocrine-tumors-93CH-4463412", "source_name": "Investing.com Australia", "published_at": "2026-05-30T14:40:31", "published_display": "30 May 2026 14:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis says Cabometyx reduces risk of progression or death by 74% in non-functional net, 60% in functional net", "summary": "Exelixis announced that its drug Cabometyx significantly reduced the risk of disease progression or death in patients with non-functional and functional neuroendocrine tumors (NETs). Specifically, Cabometyx demonstrated a 74% reduction in risk for those with non-functional NETs a", "url": "https://www.marketscreener.com/news/exelixis-says-cabometyx-reduces-risk-of-progression-or-death-by-74-in-non-functional-net-60-in-fu-ce7f5dd8db8aff24", "source_name": "marketscreener.com", "published_at": "2026-05-30T13:40:31", "published_display": "30 May 2026 13:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis, Inc. (EXEL): Renaissance Technologies Likes This Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQSHYwb3FuNkNURUNHYTgtSV9NRVFGMW83TEVkcFd6MGdSbHFoYWEwQ3g0bFFZdTNTTFZLZTFPaWlDNzhfSVBCSzFlMGJkbUdvOXdsYkpZbjdoeVBWa2o4OUlrQnBES2hXRDg0YUVUcDRzdlZfbDJtbURKc3I5TGp6Ny0wY2tQQlpKTUZUeno2TERKX0hYMFY5aHZVX1dWMjNhNjRaX0JXdmh5WlE?oc=5", "source_name": "Market source", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxOcVYwOTZJLUJTa1VMVFVJZXFWSE1oOXFCWEEtNVAyRy0yNzdEYjc3SDgtb21OZ1M0V2hackNUMnJCSng4Q1RHN1g1YUNIRFV5blJOV3dBSHJPTU9hc2JLdkNoVkMwcGZ4OEhfODBUN2FoUnJnbHg1VldfYXFfaTZjRTNqOG4wa3kwVTZTX1VRNVU2TWNEajBHSGZZR0pZUHo4SjJoS29hUldUZXBWOXhadXk5bVI5MXdib2xPUmZpWGs2TVJXQWdzTkE3UWVrbUlEMktmYVQ1d2xwZw?oc=5", "source_name": "Business Wire", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis (EXEL) director receives option grant tied to Caligan funds", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZEQta19kZnQyU3BDak1KUEdtYjZzODNmc2xOQ1dLWWtjRE9hM1E5Rm5lNFpNMTJ3OVdTcGxVTkQtU2tudTF5T3BoVy1SWERPX0VOU3padWJrZXA4ckNVT3ZMRkIxXzQ5MF9udWc5M0tOTlY3NVhFbmNzbUd5RW00RUdwTnU4c0Nub0tFX09Qa3V4OVNsa2k3bzROWnFvb2JEMFprMTcxbi1lQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Exelixis (EXEL) Story Is Shifting As Wall Street Reworks Fair Value Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPWnV5UkZmd3lUTE1kWWRkc0lybGxLNU1kQnl1NXVYRDhlS01JSk5RbjdCU2JCaHdueGd6RElrcG42Nnl1cW9WaWtIRzZ1TVA5S0g2QnNSSm1mSi1LcS1UWE5XdWdLLTlYSTY3aUhndFF3cVR3cV9ZeENoT25NWUoxUExqZVFYMVkzWGdUU2F6anB0SVh2UUoxWjJERUdSZDQ?oc=5", "source_name": "Market source", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Exelixis Insiders Been Selling Stock?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EXEL (NASDAQ: EXEL) executive files Form 144 to sell compensation shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPZnM3d1gzbXBrdms4eF9MeklfakhabmQ4VFZza0l2X0JQdTBqM2ozT0V4akxtRm8zU0lqZlNMUEN1OTFlSThuRG81QWZQMGVNdWhKWFpMbGplbTBNVlJhZnppalB3c1c2MUpLSWRzNFloZ2RkQjhYb0Q5cHJGb0JJSkw5WVhoU2J1VG1fWnBCYXdBV1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis: Financial Performance Improves Faster Than Market Expectations (NASDAQ:EXEL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQTGF3SGJ5TW9nSmYxblBpWHcyemtITlFHUHVtUnphUXIxRV82NTMwRlhWYV9pM3EyNnR6WmhWZjFUVWpBNDROWl85ZHdoVkVVdjZhX2M4SWs2YmkxUzdtd0FXNzZaZklxVUh6ci1UOHducERGenBXX1M4VE12d0dlSDItb1VWUUg2eWdXYUlZYXY2dHZieFVVZnpNOU5QdC14RC1jVWh3aGFrSUJTRGVLRWZEeEgwbkNaY0E?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis (EXEL) EVP Haley sells 32,110 shares, retains 357,638", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxORjlLRlVsNTVrUzhXQjVvSFBaMFpVT2laelE0M0ljOVN2cXRTNVJSejRnWUF5NkYyLTBMajcwbkpCdlhqdDdBWkxCNTYxZVZpSzNibkRjcnBoU1VuM25fRlBPanZwMVN2a3RvcVNrbUJQeF8zdHB2Tmh6eFhoNUtWa1dMaUpHTTNGVW00ZGl1eEk4MXBUZnhyb3RaZE5QWEhvVkp1Q185UlpsZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis Inc stock (US30161Q1040): oncology player in focus after latest earnings and pipeline updat", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxObi1LRzBESGxYSUJSMHRpUmIxQWNFS0gza0lfRUFGVXZVcVR5a3l3VDRXcUZ6c2FYcE1hSmJSQlBtUHFQdFItTW9MSExxS1JuRmk1SEFDODN6ZVctY2pNcVl3OS1kWUVDdGZnREpMY2VpU05vam1kX0VGaXJnZ1FGNGhSMlhRQUJ5UEtpdzhEODNldk5yWXdsRnYtWWN6SWxmRzNONTVqMjUtbkoxbjM5Q1NxR1lBQVY0VFVzc3ZXTF95dFJOWFRR?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Exelixis Stock Utilizing Systematic Share Retirement for Long-Term Alpha?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxNTkZ1WVozUXMyVGlfZkJJQWhOTDNxVkdIMm9Hamo4ckt0bnc1QnhCNVpPMUhSYUVwdy1reUI3UFBaVTF0VkVuNkQwUzh4WUpsc2JiQktWeVBsRUlpdDhGbDFmZE9pNUFBVVVNVmk4YmF4WlBqbzZJRFpUTXBWWGN6M0FsYVQzX0I4eXZxR05Ua0dyQ2l0MGdxdFdoYnVVdkhQWDRMWFpLTUJTb2NhTGkxN1JiNUh0Q0ZSZ3pvZzFqd3RuYjJpWFAtMmlnWkRPazZwOWc?oc=5", "source_name": "Trefis", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis stock (US30161Q1040): New data and pipeline catalysts in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNYlZwdi1JSjdKSVpfN3p2SE1Bc0E3SmhhUk04MUwtdVh6NlZhNDNSRUJxYkNDamVLNG1HMGpJT1NtSVZUWjRabVJUSDNkRGRiT1ZybmE5ZDJCVnczZnB1ZlJPeGJFdVNkaXFKQWNqdVh5SmVVUTJSRXk1TVB0ZmphcFAzb1ZNX1BZMGFIbXBIOUZzMXQwamxnVVBaX2JLN0U2bnV2clJucU1fS0NRZlg1ckVsUTFiVVAwOERLUjZhaWhKVElfUWc?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Exelixis (EXEL) Margin Expansion To 35.1% Challenges Bearish Pricing Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Exelixis (EXEL) is a Strong Value Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQOFN0RWozNDdGWm9KS1B2WVpkbldvOXhORFA2bEZCbTloeXo0ZzBLSW1TcmhWVmp6dGJrRUhfaUNFUDdUbmFKaWdjNXlVTmgtZEYxNS1YZmRNblpLVUx4TXZybzhEOU5RVnNLTDQzQy1GZ1hLcFU0RU1KZUl0eVA0Z1lrNU12amR4eHczd3lYUUU4a3lUR2x3NVRQRQ?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPMVRNeXZEVXpscmdtY3lJbjQ5WklaZGdBZHY1TDBUNGI3YjhuNjJDOWR4em5tUzNPTng2TTR5NlZrMXQ0N0N2REUyZ3ZZNnJHSWxHM084NFNtNUxaX1Rha0xtMHA0bWRCRHoxOXBfSF82Q0lCRk9YVmtOQUxQeW5kaVhDRS1naWdGQjlsYlVWV0xLbnpfVjM5NkNZQ3hUZw?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Exelixis (EXEL) Valuation After Mixed Share Performance And CABOMETYX Growth Narrative", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNYVZ0NWt3cDZYTVNrQWdDX2RRSVk0cmF6a2hYamh2ODhwVEM3cUN5b0pOaXpWS1d6NE43WXZCTm1BWWY1QWZVMWhDY2ZQQXJwMUpScnFRSFJUZ09OY1M0Qzh4VnZKT2wyMEtaUFNBTF9Xa3VvV0VhU2Y5ZkdhNDVsN1RReE1SNEh0OTdMcW5SWXN1UGJfUEpERHdicWNpNFF0eWlrN1VIbw?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Exelixis (EXEL) After Strong Five Year Share Price Gains?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Assessing Exelixis (EXEL) Valuation After Recent Short Term Share Price Pressure", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQRWEwZHE4a04zMU5WSjhNZHFUa1ZOUVl5R2ZyZ3R5MzhnOEtmaDJZajlrUXprZThpZmhLOGlNUldQQ0x3bU5GaE9lZ0dqazNhZ0haVkF6WU1xY2MwTGhZSDVHUVJZeTVrcEtGMm5vcWdKbG9JaWxMNzBYc2FpZ2RSaE03T29WclZRTTU4cUtBSEFxcVp2d095S3hQWDVXZTZ2NjNTNkUtd3E?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Value Investment Case", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOeFphZjB1Z1E4YW5tNjdjWEh2ZkdYWkZwT0dkVThIMkFQXzlYYjZWLW85Z0NtSWpmZHYxcWhSeHFmUHNTZWZsUFFDTVd1TE1sbnhNc2NJTWRGMnlocXhfWWVSc2VrUnRJVGdaZ05MSXFKcDNMQVlRWm85Ym93V1BPZnBlbzVnZG1TUmFoVHNDZUFhOVR1QW93MkpjVXBiMFJsa2gxbVQyVndUTUZ2VzNDNDRRQ25jTWxsd3FR?oc=5", "source_name": "ChartMill", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Exelixis (EXEL) After Its Surging Share Price?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPWlkzcUZhMzlpUDVaaUpfdmFLblpIcEJRaWFidmRoWVFCSGRwcUxsVnp5R0ZKSmw2TGtQZmpreHktNW9QQUtiejliV0FFYVp3R0lFQ3Aybm1BbU00R0lfU0ZsMkVWWE5wSk1oYTh1UUt4Q012SUstWVdVYmVnTWVjT25IVHdOLWM?oc=5", "source_name": "Market source", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxPc1dXb0JEbE53VldxdVNJcFl1Ykp2bFVKODlWRXd3TjE0dVhGZlVfR2JQbU5RTUJGZmZfV1hxcTIxTU1TUmZxZHhOMGRXMVMySEhtbHVHeUZzQUlIX2tQbUp3VGhhMmwyYVRMZGhIdUJsRVZSeXdKZ1gwZGtyNUV2NlpoOEZGVXpsOERtTHFOSXlyNFR3YVRnaFFrdnlfaE5keDhBX2ZkRjhTaTV2eFUydUwxLXNud25qcnlNRkhyMzFaa1ZYTmJLZkl0NVN0ZVFpNm4tbkl3aGg2ZjZ2UENNTkhPdm5vWkxIZWVTcTN2c3U?oc=5", "source_name": "Business Wire", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Value Investors Buy Exelixis (EXEL) Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOZXNDY1VtUTdhVHpHc0Z2ZU55a25kUjQ3RFA0RjU2X194Y1RMNEw3bG5WVGhMQ09PNzE2bkdWa1RVX3EzVjVUWFYzczVna1FtZGk4VmZPaG5pVEdOUjd5VVp1ckd2RkxUWUF5Z1VhMlVKWmVyYXdrR1BiY09OQ3Y2Y3FWaTVkUQ?oc=5", "source_name": "Market source", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Exelixis falls as final analysis of zanzalintinib phase 3 data disappoints", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOd3NUMmVlc2dfT1ZTMGZoaGlpUVhqQzg5VVJ5bWZUZXBvbVdNVHZOZzMzcENCWFpxUFZmR3NWa3ZLa3daSTZBR3RseUFhTjJHbmNNRFRWU1pyNzl3VXJGRUsxbG1GMGFlQ3Y5YjZrcVJrSXdJV1NHVjFkZkRmY1VGM0h1NmJVR3A5aWNNVzNWQVRNaGxvNlc1TjdiSkhyMmdxTXZ6N1JrVE1kZw?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-06-22T15:14:23+00:00", "published_display": "22 Jun 2026 15:14", "sentiment": "negative", "sentiment_pct": 18, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis Stock - weekly review and biotech sector context", "summary": "", "url": "https://news.google.com/rss/articles/CBMitAFBVV95cUxNV09NdjFDWDhnbGl5ZDg2eHdKWU5aemstR1pCeVNVMTJJSWFfOW5Ud2VYYlc0Vk9JSEdoRUVXOEk5YkZIRjNaaXc1bi1Td0Z3ajNFWEFhOGtkLTBfVXFrRldvWjA5ODVxQnNuem9zM0VESlYySVhJd194YkNHMlR0NFNkQTVqd3lVMFp6NFBwcmVacE1KRm1LbXZLcDE2WXNfdFlFckNLOEY1UWd0bXpaTWpEZUY?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-06-19T20:46:53+00:00", "published_display": "19 Jun 2026 20:46", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis Inc (EXEL) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "This article provides an earnings forecast for Exelixis Inc (EXEL), highlighting its current earnings forecast score, analyst ratings, and price targets. It details expected EPS and revenue for upcoming quarters and compares EXEL's analyst ratings to its peers in the Biotechnolog", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-exel/earnings", "source_name": "TradingKey", "published_at": "2026-06-18T09:10:21", "published_display": "18 Jun 2026 09:10", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis Inc (EXEL) Financial Health: Profitability & Balance Sheet Analysis", "summary": "Exelixis Inc (EXEL) demonstrates robust financial health with a score of 8.96, ranking 21st in the Biotechnology & Medical Research industry. The company reported a significant year-over-year revenue increase of 9.97% to $610.81M and a net profit increase of 31.86%. This strong p", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-exel/financial-health", "source_name": "TradingKey", "published_at": "2026-06-18T06:10:22", "published_display": "18 Jun 2026 06:10", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Investors Are Reacting To Exelixis (EXEL) CABOMETYX Neuroendocrine Tumor Phase 3 Win at ASCO", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-17T14:57:27+00:00", "published_display": "17 Jun 2026 14:57", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis Inc (EXEL) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for Exelixis Inc (EXEL), categorizing its income by business segments and geographical regions. As of April 6, 2025, CABOMETYX is the primary revenue driver, contributing 91.09% of the total, with the U.S. market dominating regio", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-exel/revenue", "source_name": "TradingKey", "published_at": "2026-06-17T08:41:23", "published_display": "17 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis Inc (EXEL) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides an overview of Exelixis Inc's (EXEL) shareholder structure, listing major institutional holders and their proportion of shares. It details shareholder types, institutional shareholding trends over recent quarters, and individual shareholder activity with cha", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-exel/ownership", "source_name": "TradingKey", "published_at": "2026-06-17T08:41:23", "published_display": "17 Jun 2026 08:41", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis Inc Stock (US30161Q1040): Quarterly earnings in focus after recent results", "summary": "Exelixis Inc reported its first-quarter 2024 financial results, showing revenue growth driven primarily by its flagship cancer drug, Cabometyx. The company also provided an updated 2024 financial outlook, projecting continued revenue growth despite increased R&D spending to furth", "url": "https://www.ad-hoc-news.de/boerse/news/ueberblick/exelixis-inc-stock-us30161q1040-quarterly-earnings-in-focus-after/69545115", "source_name": "AD HOC NEWS", "published_at": "2026-06-15T14:09:24", "published_display": "15 Jun 2026 14:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why (EXEL) Price Action Is Critical for Tactical Trading", "summary": "This article from Stock Traders Daily discusses the critical price action of Exelixis Inc. (NASDAQ: EXEL) for tactical trading, based on AI-driven analysis. It highlights strong sentiment across all time horizons, indicating an overweight bias, and identifies potential upside. Th", "url": "https://news.stocktradersdaily.com/news_release/20/Why_EXEL_Price_Action_Is_Critical_for_Tactical_Trading_061526040402_1781510642.html", "source_name": "Stock Traders Daily", "published_at": "2026-06-15T04:04:00", "published_display": "15 Jun 2026 04:04", "sentiment": "positive", "sentiment_pct": 71, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis CABINET Win Extends CABOMETYX Reach And Raises Valuation Questions", "summary": "Exelixis reported positive phase 3 CABINET trial results for CABOMETYX in advanced neuroendocrine tumors, demonstrating significant improvement in progression-free survival. This extends the potential reach of CABOMETYX, but given the stock's strong performance, investors are eva", "url": "https://sg.finance.yahoo.com/news/exelixis-cabinet-win-extends-cabometyx-200859000.html", "source_name": "Market source", "published_at": "2026-06-13T20:08:00", "published_display": "13 Jun 2026 20:08", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Goldman Sachs Group Inc. Purchases 1,113,916 Shares of Exelixis, Inc. $EXEL", "summary": "Goldman Sachs Group Inc. significantly increased its stake in Exelixis, Inc. (NASDAQ:EXEL) during the fourth quarter, purchasing over 1.1 million additional shares, raising its total holding to 2.1 million shares valued at approximately $92.7 million. Following this news, Exelixi", "url": "https://www.marketbeat.com/instant-alerts/filing-goldman-sachs-group-inc-purchases-1113916-shares-of-exelixis-inc-exel-2026-06-10/", "source_name": "MarketBeat", "published_at": "2026-06-11T03:39:16", "published_display": "11 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 70, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Cibc World Market Inc. Purchases 31,985 Shares of Exelixis, Inc. $EXEL", "summary": "Cibc World Market Inc. significantly increased its stake in Exelixis, Inc. by 462.3% in the fourth quarter, adding 31,985 shares to hold a total of 38,904 shares valued at $1.705 million. This move is part of a broader trend, with other institutional investors also boosting their", "url": "https://www.marketbeat.com/instant-alerts/filing-cibc-world-market-inc-purchases-31985-shares-of-exelixis-inc-exel-2026-06-10/", "source_name": "MarketBeat", "published_at": "2026-06-10T16:39:28", "published_display": "10 Jun 2026 16:39", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "BI Asset Management Fondsmaeglerselskab A S Has $1.91 Million Position in Exelixis, Inc. $EXEL", "summary": "BI Asset Management Fondsmaeglerselskab A S significantly reduced its stake in Exelixis, Inc. by 74.9% in the fourth quarter, now holding 43,658 shares valued at approximately $1.91 million. This comes as several insiders, including CFO Christopher J. Senner and Director Sue Gail", "url": "https://www.marketbeat.com/instant-alerts/filing-bi-asset-management-fondsmaeglerselskab-a-s-has-191-million-position-in-exelixis-inc-exel-2026-06-10/", "source_name": "MarketBeat", "published_at": "2026-06-10T15:39:43", "published_display": "10 Jun 2026 15:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis (EXEL) Valuation Check After CABINET Trial Data Fuels Renewed Growth Optimism", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-06-10T07:00:00+00:00", "published_display": "10 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Bank of New York Mellon Corp Cuts Position in Exelixis, Inc. $EXEL", "summary": "Bank of New York Mellon Corp reduced its stake in Exelixis, Inc. by 12.3% during the fourth quarter, selling 285,584 shares. Despite this, other institutional investors like Goldman Sachs Group Inc. and BNP Paribas Financial Markets increased their holdings significantly. Exelixi", "url": "https://www.marketbeat.com/instant-alerts/filing-bank-of-new-york-mellon-corp-cuts-position-in-exelixis-inc-exel-2026-06-09/", "source_name": "MarketBeat", "published_at": "2026-06-10T03:39:16", "published_display": "10 Jun 2026 03:39", "sentiment": "positive", "sentiment_pct": 62, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis stock hits all-time high at 52.98 USD By Investing.com", "summary": "Exelixis Inc. (EXEL) stock reached an all-time high of $52.98, reflecting a 24.86% increase over the past year. The biotechnology company, currently valued at $13.34 billion, shows an attractive P/E ratio of 17.08 and a PEG ratio of 0.42, suggesting undervaluation and strong near", "url": "https://ng.investing.com/news/company-news/exelixis-stock-hits-alltime-high-at-5298-usd-93CH-2550204", "source_name": "Investing.com Nigeria", "published_at": "2026-06-09T14:41:04", "published_display": "09 Jun 2026 14:41", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis, Inc. $EXEL Position Increased by Northwestern Mutual Wealth Management Co.", "summary": "Northwestern Mutual Wealth Management Co. significantly increased its stake in Exelixis, Inc. by 2,920.5% in the fourth quarter, now owning 25,040 shares valued at $1.1 million. This increase comes as Exelixis reported strong quarterly results, beating EPS estimates with $0.87 an", "url": "https://www.marketbeat.com/instant-alerts/filing-exelixis-inc-exel-position-increased-by-northwestern-mutual-wealth-management-co-2026-06-08/", "source_name": "MarketBeat", "published_at": "2026-06-09T04:10:42", "published_display": "09 Jun 2026 04:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis, Inc. (EXEL) Stock Analysis: A Promising Player in Biotechnology with Strong Revenue Growth", "summary": "Exelixis, Inc. (EXEL) is highlighted as a significant player in the biotechnology sector, specializing in cancer treatments with products like CABOMETYX and COMETRIQ. The company demonstrates strong financial performance with 10% year-over-year revenue growth and a High ROE of 40", "url": "https://www.directorstalkinterviews.com/exelixis-inc-exel-stock-analysis-a-promising-player-in-biotechnology-with-strong-revenue-growth/4121253186", "source_name": "DirectorsTalk Interviews", "published_at": "2026-06-08T10:14:00", "published_display": "08 Jun 2026 10:14", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "CABINET Results Broaden CABOMETYX Neuroendocrine Reach And Investor Considerations", "summary": "Exelixis, Inc. reported new phase 3 CABINET trial data for CABOMETYX in advanced neuroendocrine tumors, showing significant improvements in progression-free survival regardless of tumor functional status. These results expand the clinical evidence for CABOMETYX and reinforce its ", "url": "https://www.sahmcapital.com/news/content/cabinet-results-broaden-cabometyx-neuroendocrine-reach-and-investor-considerations-2026-06-06", "source_name": "Sahm", "published_at": "2026-06-07T01:39:52", "published_display": "07 Jun 2026 01:39", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis director Sue Eckhardt sells $491,973 in stock", "summary": "Exelixis director Sue Eckhardt sold 9,812 shares of the company's common stock for $491,973 on June 1, 2026, as part of a Rule 10b5-1 trading plan. The sale occurred while the stock was near its 52-week high, though InvestingPro analysis suggests it is still undervalued with exce", "url": "https://www.investing.com/news/insider-trading-news/exelixis-director-sue-eckhardt-sells-491973-in-stock-93CH-4725458", "source_name": "Investing.com", "published_at": "2026-06-04T13:40:32", "published_display": "04 Jun 2026 13:40", "sentiment": "negative", "sentiment_pct": 40, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis director Jack Wyszomierski sells $198,408 in shares", "summary": "Jack L. Wyszomierski, a director at Exelixis Inc. (NASDAQ:EXEL), recently sold 3,925 shares of the company's common stock for $198,408. This transaction was executed under a Rule 10b5-1 trading plan. The article also notes Exelixis' strong financial performance in Q1 2026 and its", "url": "https://www.investing.com/news/insider-trading-news/exelixis-director-jack-wyszomierski-sells-198408-in-shares-93CH-4725459", "source_name": "Investing.com", "published_at": "2026-06-04T12:40:30", "published_display": "04 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxNbE5NTHBCdDV1S1Y0b2hJTU9SbmdNTi1yRV9SYzNUOVhYYzR1R1FtdGtnTjVOWk02akNVMV94VENqUmw2dWdRNzJqNXhyOGxaNVpxOHd4alhBaUhBYVU5NzJ4bGF5VVA3YzFNdlBMTHotcVZCd2ZHSG9EQ1hGb05RV1l5dVlnM080aVpTTlp0bFBIU3hoWHllMw?oc=5", "source_name": "Market source", "published_at": "2026-06-04T07:00:00+00:00", "published_display": "04 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EXEL Financials: Revenue Breakdown, Margins & Competitor Comparison", "summary": "This article provides a detailed financial analysis of Exelixis Inc (EXEL), outlining its revenue breakdown, profitability margins, and a comparison with key competitors RGC and MDGL. It highlights that CABOMETYX is the primary revenue driver, contributing 90.3% of total sales, a", "url": "https://intellectia.ai/en/stock/EXEL/financials", "source_name": "Intellectia AI", "published_at": "2026-06-04T04:39:16", "published_display": "04 Jun 2026 04:39", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "[144] EXELIXIS, INC. SEC Filing", "summary": "This SEC filing refers to a Form 144 filed by Exelixis, Inc. (EXEL) on June 1, 2026, indicating a proposed sale of securities. The document outlines the information required for such a sale under Rule 144, including details about the securities to be sold (9812 shares of common s", "url": "https://www.stocktitan.net/sec-filings/EXEL/144-exelixis-inc-sec-filing-06e92a1a37bb.html", "source_name": "Stock Titan", "published_at": "2026-06-04T03:09:27", "published_display": "04 Jun 2026 03:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Insider Sell Alert: Jack Wyszomierski Sells 3,925 Shares of Exelixis Inc (EXEL)", "summary": "Jack Wyszomierski, a Director at Exelixis Inc (EXEL), sold 3,925 shares of the company on June 1, 2026, increasing his total sales over the past year to 103,499 shares. Exelixis, a biotechnology company focused on cancer treatments, has seen 1 insider buy and 21 insider sells in ", "url": "https://www.gurufocus.com/news/8900093/insider-sell-alert-jack-wyszomierski-sells-3925-shares-of-exelixis-inc-exel", "source_name": "GuruFocus", "published_at": "2026-06-04T00:11:42", "published_display": "04 Jun 2026 00:11", "sentiment": "negative", "sentiment_pct": 37, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Planned share sale by Exelixis (NASDAQ: EXEL) director Wyszomierski", "summary": "Exelixis director Jack L. Wyszomierski sold 3,925 shares of common stock at $50.55 per share on June 1, 2026. This transaction was part of a pre-arranged Rule 10b5-1 trading plan adopted in November 2025. Following the sale, he directly holds 284,384 shares, with an additional 8,", "url": "https://www.stocktitan.net/sec-filings/EXEL/form-4-exelixis-inc-insider-trading-activity-6ef5b77ec34f.html", "source_name": "Stock Titan", "published_at": "2026-06-03T23:10:06", "published_display": "03 Jun 2026 23:10", "sentiment": "negative", "sentiment_pct": 39, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis (EXEL) director Eckhardt sells 9,812 shares under 10b5-1 plan", "summary": "Exelixis (EXEL) director Sue Gail Eckhardt sold 9,812 shares of common stock at a weighted average price of $50.14 per share on June 1, 2026, under a pre-arranged Rule 10b5-1 trading plan. Following the transaction, her total holdings include 16,079 shares, which account for rest", "url": "https://www.stocktitan.net/sec-filings/EXEL/form-4-exelixis-inc-insider-trading-activity-f7ad9d426627.html", "source_name": "Stock Titan", "published_at": "2026-06-03T23:10:06", "published_display": "03 Jun 2026 23:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis Jumps 5.0% Amid Sector-Wide Rally", "summary": "Exelixis, Inc. saw its stock price surge by 5.0% to $50.99 on Wednesday, driven by a broader rally in the biotechnology sector. This rise, which included similar gains for several peer companies like Incyte and Moderna, was attributed to sector-wide momentum rather than any speci", "url": "https://news.alphastreet.com/exelixis-jumps-5-0-amid-sector-wide-rally/", "source_name": "AlphaStreet", "published_at": "2026-06-03T17:10:06", "published_display": "03 Jun 2026 17:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Why Exelixis (EXEL) is a Top Value Stock for the Long-Term", "summary": "", "url": "https://news.google.com/rss/articles/CBMilwFBVV95cUxQemt0SXozdDh4S29GS2taZXJ1SEpqLXVSOElobU12RmtMR0RmckFVNEpNcWpKODZCblpvSmpqRmhfMzQtcl9HSlBYaXEyeGFwNmZ3UHk2VF9QRjBXeGc1Rmx1UFZFb3B1TjJSN0ZhTS04anVFcTNtN3dKT25fRjlvN1h6Mm1sQkxaT2FsOFVsV2dpRzZYVUFN?oc=5", "source_name": "Market source", "published_at": "2026-06-03T07:00:00+00:00", "published_display": "03 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis, Inc. $EXEL Shares Purchased by BNP Paribas Financial Markets", "summary": "BNP Paribas Financial Markets significantly increased its stake in Exelixis, Inc. (NASDAQ:EXEL) by 79.5% during the fourth quarter, bringing its total holdings to over 1.1 million shares valued at approximately $49 million. This increase follows Exelixis reporting better-than-exp", "url": "https://www.marketbeat.com/instant-alerts/filing-exelixis-inc-exel-shares-purchased-by-bnp-paribas-financial-markets-2026-06-03/", "source_name": "MarketBeat", "published_at": "2026-06-01T17:09:24", "published_display": "01 Jun 2026 17:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis presents Cabometyx data for neuroendocrine tumors", "summary": "Exelixis (NASDAQ:EXEL) presented positive subgroup analysis data from its phase 3 CABINET trial for Cabometyx in neuroendocrine tumors at the American Society of Clinical Oncology Annual Meeting. The results showed a significant reduction in the risk of disease progression or dea", "url": "https://www.investing.com/news/company-news/exelixis-presents-cabometyx-data-for-neuroendocrine-tumors-93CH-4717767", "source_name": "Investing.com", "published_at": "2026-05-31T11:10:13", "published_display": "31 May 2026 11:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis presents Cabometyx data for neuroendocrine tumors By Investing.com", "summary": "Exelixis (NASDAQ:EXEL) has released positive subgroup analysis results from its Phase 3 CABINET trial for Cabometyx in advanced neuroendocrine tumors. The study showed significant reduction in disease progression or death risk in both functional and non-functional tumor patients.", "url": "https://au.investing.com/news/stock-market-news/exelixis-presents-cabometyx-data-for-neuroendocrine-tumors-93CH-4463412", "source_name": "Investing.com Australia", "published_at": "2026-05-30T14:40:31", "published_display": "30 May 2026 14:40", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis says Cabometyx reduces risk of progression or death by 74% in non-functional net, 60% in functional net", "summary": "Exelixis announced that its drug Cabometyx significantly reduced the risk of disease progression or death in patients with non-functional and functional neuroendocrine tumors (NETs). Specifically, Cabometyx demonstrated a 74% reduction in risk for those with non-functional NETs a", "url": "https://www.marketscreener.com/news/exelixis-says-cabometyx-reduces-risk-of-progression-or-death-by-74-in-non-functional-net-60-in-fu-ce7f5dd8db8aff24", "source_name": "marketscreener.com", "published_at": "2026-05-30T13:40:31", "published_display": "30 May 2026 13:40", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis, Inc. (EXEL): Renaissance Technologies Likes This Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqwFBVV95cUxQSHYwb3FuNkNURUNHYTgtSV9NRVFGMW83TEVkcFd6MGdSbHFoYWEwQ3g0bFFZdTNTTFZLZTFPaWlDNzhfSVBCSzFlMGJkbUdvOXdsYkpZbjdoeVBWa2o4OUlrQnBES2hXRDg0YUVUcDRzdlZfbDJtbURKc3I5TGp6Ny0wY2tQQlpKTUZUeno2TERKX0hYMFY5aHZVX1dWMjNhNjRaX0JXdmh5WlE?oc=5", "source_name": "Market source", "published_at": "2026-05-30T07:00:00+00:00", "published_display": "30 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis Announces First Quarter 2026 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2gFBVV95cUxOcVYwOTZJLUJTa1VMVFVJZXFWSE1oOXFCWEEtNVAyRy0yNzdEYjc3SDgtb21OZ1M0V2hackNUMnJCSng4Q1RHN1g1YUNIRFV5blJOV3dBSHJPTU9hc2JLdkNoVkMwcGZ4OEhfODBUN2FoUnJnbHg1VldfYXFfaTZjRTNqOG4wa3kwVTZTX1VRNVU2TWNEajBHSGZZR0pZUHo4SjJoS29hUldUZXBWOXhadXk5bVI5MXdib2xPUmZpWGs2TVJXQWdzTkE3UWVrbUlEMktmYVQ1d2xwZw?oc=5", "source_name": "Business Wire", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis (EXEL) director receives option grant tied to Caligan funds", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxOZEQta19kZnQyU3BDak1KUEdtYjZzODNmc2xOQ1dLWWtjRE9hM1E5Rm5lNFpNMTJ3OVdTcGxVTkQtU2tudTF5T3BoVy1SWERPX0VOU3padWJrZXA4ckNVT3ZMRkIxXzQ5MF9udWc5M0tOTlY3NVhFbmNzbUd5RW00RUdwTnU4c0Nub0tFX09Qa3V4OVNsa2k3bzROWnFvb2JEMFprMTcxbi1lQQ?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How The Exelixis (EXEL) Story Is Shifting As Wall Street Reworks Fair Value Targets", "summary": "", "url": "https://news.google.com/rss/articles/CBMinwFBVV95cUxPWnV5UkZmd3lUTE1kWWRkc0lybGxLNU1kQnl1NXVYRDhlS01JSk5RbjdCU2JCaHdueGd6RElrcG42Nnl1cW9WaWtIRzZ1TVA5S0g2QnNSSm1mSi1LcS1UWE5XdWdLLTlYSTY3aUhndFF3cVR3cV9ZeENoT25NWUoxUExqZVFYMVkzWGdUU2F6anB0SVh2UUoxWjJERUdSZDQ?oc=5", "source_name": "Market source", "published_at": "2026-05-29T07:00:00+00:00", "published_display": "29 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Have Exelixis Insiders Been Selling Stock?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "EXEL (NASDAQ: EXEL) executive files Form 144 to sell compensation shares", "summary": "", "url": "https://news.google.com/rss/articles/CBMikwFBVV95cUxPZnM3d1gzbXBrdms4eF9MeklfakhabmQ4VFZza0l2X0JQdTBqM2ozT0V4akxtRm8zU0lqZlNMUEN1OTFlSThuRG81QWZQMGVNdWhKWFpMbGplbTBNVlJhZnppalB3c1c2MUpLSWRzNFloZ2RkQjhYb0Q5cHJGb0JJSkw5WVhoU2J1VG1fWnBCYXdBV1E?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-26T07:00:00+00:00", "published_display": "26 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis: Financial Performance Improves Faster Than Market Expectations (NASDAQ:EXEL)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiugFBVV95cUxQTGF3SGJ5TW9nSmYxblBpWHcyemtITlFHUHVtUnphUXIxRV82NTMwRlhWYV9pM3EyNnR6WmhWZjFUVWpBNDROWl85ZHdoVkVVdjZhX2M4SWs2YmkxUzdtd0FXNzZaZklxVUh6ci1UOHducERGenBXX1M4VE12d0dlSDItb1VWUUg2eWdXYUlZYXY2dHZieFVVZnpNOU5QdC14RC1jVWh3aGFrSUJTRGVLRWZEeEgwbkNaY0E?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-05-23T07:00:00+00:00", "published_display": "23 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis (EXEL) EVP Haley sells 32,110 shares, retains 357,638", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqgFBVV95cUxORjlLRlVsNTVrUzhXQjVvSFBaMFpVT2laelE0M0ljOVN2cXRTNVJSejRnWUF5NkYyLTBMajcwbkpCdlhqdDdBWkxCNTYxZVZpSzNibkRjcnBoU1VuM25fRlBPanZwMVN2a3RvcVNrbUJQeF8zdHB2Tmh6eFhoNUtWa1dMaUpHTTNGVW00ZGl1eEk4MXBUZnhyb3RaZE5QWEhvVkp1Q185UlpsZw?oc=5", "source_name": "Stock Titan", "published_at": "2026-05-22T07:00:00+00:00", "published_display": "22 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis Inc stock (US30161Q1040): oncology player in focus after latest earnings and pipeline updat", "summary": "", "url": "https://news.google.com/rss/articles/CBMixwFBVV95cUxObi1LRzBESGxYSUJSMHRpUmIxQWNFS0gza0lfRUFGVXZVcVR5a3l3VDRXcUZ6c2FYcE1hSmJSQlBtUHFQdFItTW9MSExxS1JuRmk1SEFDODN6ZVctY2pNcVl3OS1kWUVDdGZnREpMY2VpU05vam1kX0VGaXJnZ1FGNGhSMlhRQUJ5UEtpdzhEODNldk5yWXdsRnYtWWN6SWxmRzNONTVqMjUtbkoxbjM5Q1NxR1lBQVY0VFVzc3ZXTF95dFJOWFRR?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is Exelixis Stock Utilizing Systematic Share Retirement for Long-Term Alpha?", "summary": "", "url": "https://news.google.com/rss/articles/CBMi0gFBVV95cUxNTkZ1WVozUXMyVGlfZkJJQWhOTDNxVkdIMm9Hamo4ckt0bnc1QnhCNVpPMUhSYUVwdy1reUI3UFBaVTF0VkVuNkQwUzh4WUpsc2JiQktWeVBsRUlpdDhGbDFmZE9pNUFBVVVNVmk4YmF4WlBqbzZJRFpUTXBWWGN6M0FsYVQzX0I4eXZxR05Ua0dyQ2l0MGdxdFdoYnVVdkhQWDRMWFpLTUJTb2NhTGkxN1JiNUh0Q0ZSZ3pvZzFqd3RuYjJpWFAtMmlnWkRPazZwOWc?oc=5", "source_name": "Trefis", "published_at": "2026-05-21T07:00:00+00:00", "published_display": "21 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis stock (US30161Q1040): New data and pipeline catalysts in focus", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxNYlZwdi1JSjdKSVpfN3p2SE1Bc0E3SmhhUk04MUwtdVh6NlZhNDNSRUJxYkNDamVLNG1HMGpJT1NtSVZUWjRabVJUSDNkRGRiT1ZybmE5ZDJCVnczZnB1ZlJPeGJFdVNkaXFKQWNqdVh5SmVVUTJSRXk1TVB0ZmphcFAzb1ZNX1BZMGFIbXBIOUZzMXQwamxnVVBaX2JLN0U2bnV2clJucU1fS0NRZlg1ckVsUTFiVVAwOERLUjZhaWhKVElfUWc?oc=5", "source_name": "AD HOC NEWS", "published_at": "2026-05-16T07:00:00+00:00", "published_display": "16 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis (EXEL) Margin Expansion To 35.1% Challenges Bearish Pricing Narratives", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-07T07:00:00+00:00", "published_display": "07 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 63, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Here's Why Exelixis (EXEL) is a Strong Value Stock", "summary": "", "url": "https://news.google.com/rss/articles/CBMimwFBVV95cUxQOFN0RWozNDdGWm9KS1B2WVpkbldvOXhORFA2bEZCbTloeXo0ZzBLSW1TcmhWVmp6dGJrRUhfaUNFUDdUbmFKaWdjNXlVTmgtZEYxNS1YZmRNblpLVUx4TXZybzhEOU5RVnNLTDQzQy1GZ1hLcFU0RU1KZUl0eVA0Z1lrNU12amR4eHczd3lYUUU4a3lUR2x3NVRQRQ?oc=5", "source_name": "Market source", "published_at": "2026-05-06T07:00:00+00:00", "published_display": "06 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis (EXEL) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPMVRNeXZEVXpscmdtY3lJbjQ5WklaZGdBZHY1TDBUNGI3YjhuNjJDOWR4em5tUzNPTng2TTR5NlZrMXQ0N0N2REUyZ3ZZNnJHSWxHM084NFNtNUxaX1Rha0xtMHA0bWRCRHoxOXBfSF82Q0lCRk9YVmtOQUxQeW5kaVhDRS1naWdGQjlsYlVWV0xLbnpfVjM5NkNZQ3hUZw?oc=5", "source_name": "Market source", "published_at": "2026-05-05T07:00:00+00:00", "published_display": "05 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Exelixis (EXEL) Valuation After Mixed Share Performance And CABOMETYX Growth Narrative", "summary": "", "url": "https://news.google.com/rss/articles/CBMipwFBVV95cUxNYVZ0NWt3cDZYTVNrQWdDX2RRSVk0cmF6a2hYamh2ODhwVEM3cUN5b0pOaXpWS1d6NE43WXZCTm1BWWY1QWZVMWhDY2ZQQXJwMUpScnFRSFJUZ09OY1M0Qzh4VnZKT2wyMEtaUFNBTF9Xa3VvV0VhU2Y5ZkdhNDVsN1RReE1SNEh0OTdMcW5SWXN1UGJfUEpERHdicWNpNFF0eWlrN1VIbw?oc=5", "source_name": "Market source", "published_at": "2026-05-02T07:00:00+00:00", "published_display": "02 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Exelixis (EXEL) After Strong Five Year Share Price Gains?", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-04-30T07:00:00+00:00", "published_display": "30 Apr 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Assessing Exelixis (EXEL) Valuation After Recent Short Term Share Price Pressure", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQRWEwZHE4a04zMU5WSjhNZHFUa1ZOUVl5R2ZyZ3R5MzhnOEtmaDJZajlrUXprZThpZmhLOGlNUldQQ0x3bU5GaE9lZ0dqazNhZ0haVkF6WU1xY2MwTGhZSDVHUVJZeTVrcEtGMm5vcWdKbG9JaWxMNzBYc2FpZ2RSaE03T29WclZRTTU4cUtBSEFxcVp2d095S3hQWDVXZTZ2NjNTNkUtd3E?oc=5", "source_name": "Market source", "published_at": "2026-04-17T07:00:00+00:00", "published_display": "17 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis Inc (NASDAQ:EXEL) Presents a Compelling Value Investment Case", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuwFBVV95cUxOeFphZjB1Z1E4YW5tNjdjWEh2ZkdYWkZwT0dkVThIMkFQXzlYYjZWLW85Z0NtSWpmZHYxcWhSeHFmUHNTZWZsUFFDTVd1TE1sbnhNc2NJTWRGMnlocXhfWWVSc2VrUnRJVGdaZ05MSXFKcDNMQVlRWm85Ym93V1BPZnBlbzVnZG1TUmFoVHNDZUFhOVR1QW93MkpjVXBiMFJsa2gxbVQyVndUTUZ2VzNDNDRRQ25jTWxsd3FR?oc=5", "source_name": "ChartMill", "published_at": "2026-02-26T08:00:00+00:00", "published_display": "26 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Is It Too Late To Consider Exelixis (EXEL) After Its Surging Share Price?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihwFBVV95cUxPWlkzcUZhMzlpUDVaaUpfdmFLblpIcEJRaWFidmRoWVFCSGRwcUxsVnp5R0ZKSmw2TGtQZmpreHktNW9QQUtiejliV0FFYVp3R0lFQ3Aybm1BbU00R0lfU0ZsMkVWWE5wSk1oYTh1UUt4Q012SUstWVdVYmVnTWVjT25IVHdOLWM?oc=5", "source_name": "Market source", "published_at": "2026-02-25T08:00:00+00:00", "published_display": "25 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Exelixis Announces Fourth Quarter and Fiscal Year 2025 Financial Results and Provides Corporate Update", "summary": "", "url": "https://news.google.com/rss/articles/CBMi8AFBVV95cUxPc1dXb0JEbE53VldxdVNJcFl1Ykp2bFVKODlWRXd3TjE0dVhGZlVfR2JQbU5RTUJGZmZfV1hxcTIxTU1TUmZxZHhOMGRXMVMySEhtbHVHeUZzQUlIX2tQbUp3VGhhMmwyYVRMZGhIdUJsRVZSeXdKZ1gwZGtyNUV2NlpoOEZGVXpsOERtTHFOSXlyNFR3YVRnaFFrdnlfaE5keDhBX2ZkRjhTaTV2eFUydUwxLXNud25qcnlNRkhyMzFaa1ZYTmJLZkl0NVN0ZVFpNm4tbkl3aGg2ZjZ2UENNTkhPdm5vWkxIZWVTcTN2c3U?oc=5", "source_name": "Business Wire", "published_at": "2026-02-10T08:00:00+00:00", "published_display": "10 Feb 2026 08:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Should Value Investors Buy Exelixis (EXEL) Stock?", "summary": "", "url": "https://news.google.com/rss/articles/CBMihgFBVV95cUxOZXNDY1VtUTdhVHpHc0Z2ZU55a25kUjQ3RFA0RjU2X194Y1RMNEw3bG5WVGhMQ09PNzE2bkdWa1RVX3EzVjVUWFYzczVna1FtZGk4VmZPaG5pVEdOUjd5VVp1ckd2RkxUWUF5Z1VhMlVKWmVyYXdrR1BiY09OQ3Y2Y3FWaTVkUQ?oc=5", "source_name": "Market source", "published_at": "2026-02-03T08:00:00+00:00", "published_display": "03 Feb 2026 08:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMipAFBVV95cUxNZXlTZHFHZVNxMktqZ0hVNURmdE1hUFpZZnlfdEVhMnVla2EyTWN6b2YwNkVhNllxUy1Bczl2a0ZUNk04Q3oyTEZSajdpMnFDVXJfRTlfLUdHQ05uS3FQZkhNWkJ0MDFENDJvRXR0ZGV1RDlYVmdWem96V29NeTg4YWRZWGNoMzM1emRoSExJbXdwZnJIWHpsYjVnT0FQVHZtUW5iVg?oc=5", "source_name": "Market source", "published_at": "2026-03-30T07:00:00+00:00", "published_display": "30 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 103, "total_relevant": 66, "sentiment_summary": {"positive": 26, "negative": 8, "neutral": 32, "score": 56, "total": 66, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "general", "primary_label": "Market update", "confidence": 79, "events": [{"event": "general", "label": "Market update", "weight": 19.95, "count": 35}, {"event": "earnings", "label": "Earnings", "weight": 14.99, "count": 29}, {"event": "regulatory", "label": "Regulatory and legal", "weight": 0.9, "count": 1}, {"event": "analyst", "label": "Analyst action", "weight": 0.55, "count": 1}], "positive_events": 26, "negative_events": 8}, "market_context": {"has_market_context": true, "latest_close": 51.91, "latest_week": "2026-06-19", "one_week_move": -2.3, "four_week_move": 3.5, "twelve_week_move": 25.0, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.180704, "market_dynamics_buy_signal": false, "relative_strength": -0.328447, "fair_value_gap": 59.2, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "positive", "expectation_probability": 56.6645, "reaction_label": "Price reacting lower", "reaction_tone": "negative", "market_sentence": "-2.3% over one week, +3.5% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Balanced read", "tone": "neutral", "classification": "balanced", "summary": "News tone and price action are not far from neutral.", "confidence": 65, "badges": [], "opportunities": [], "risks": [], "event_label": "Market update", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 16}, {"label": "simplywall.st", "count": 6}, {"label": "MarketBeat", "count": 6}, {"label": "Stock Titan", "count": 6}, {"label": "AD HOC NEWS", "count": 4}, {"label": "TradingKey", "count": 4}, {"label": "Investing.com", "count": 3}, {"label": "Seeking Alpha", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 59}, {"label": "Industry context", "count": 7}, {"label": "Sector context", "count": 0}], "events": [{"label": "Market update", "count": 35}, {"label": "Earnings", "count": 29}, {"label": "Regulatory and legal", "count": 1}, {"label": "Analyst action", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "56/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Balanced read", "tone": "neutral", "text": "News tone and price action are not far from neutral."}, {"label": "Primary event", "value": "Market update", "tone": "neutral", "text": "79/100 classification confidence."}, {"label": "Company focus", "value": "59", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "3", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "-2.3% over one week, +3.5% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Negative", "tone": "negative", "text": "Exelixis falls as final analysis of zanzalintinib phase 3 data disappoints"}], "updated_at": "2026-06-22T15:29:32.805138+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}